Galmed Pharmaceuticals Company Profile (NASDAQ:GLMD)

About Galmed Pharmaceuticals (NASDAQ:GLMD)

Galmed Pharmaceuticals logoGalmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product candidate, aramchol, is a disease modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis (NASH). The Company's Aramchol is a conjugate of cholic acid and arachidic acid, which is a member of synthetic Fatty-Acid/Bile-Acid Conjugates (FABACs). FABACs are composed of endogenic compounds. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis (NASH). Aramchol is in Phase IIb clinical trials.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:GLMD
  • CUSIP: N/A
  • Web:
  • Market Cap: $110.75 million
  • Outstanding Shares: 12,219,000
Average Prices:
  • 50 Day Moving Avg: $8.51
  • 200 Day Moving Avg: $6.62
  • 52 Week Range: $2.78 - $9.59
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.12
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $1 million
  • Price / Sales: 99.22
  • Book Value: $0.51 per share
  • Price / Book: 15.92
  • EBITDA: ($14,300,000.00)
  • Net Margins: -1,443.98%
  • Return on Equity: -141.13%
  • Return on Assets: -99.09%
  • Current Ratio: 2.60%
  • Quick Ratio: 2.60%
  • Average Volume: 36,764 shs.
  • Beta: 2.58
  • Short Ratio: 1.86

Frequently Asked Questions for Galmed Pharmaceuticals (NASDAQ:GLMD)

What is Galmed Pharmaceuticals' stock symbol?

Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD."

How were Galmed Pharmaceuticals' earnings last quarter?

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) issued its quarterly earnings results on Monday, July, 31st. The company reported ($0.22) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.33) by $0.11. The company earned $0.27 million during the quarter, compared to the consensus estimate of $0.29 million. Galmed Pharmaceuticals had a negative net margin of 1,443.98% and a negative return on equity of 141.13%. View Galmed Pharmaceuticals' Earnings History.

When will Galmed Pharmaceuticals make its next earnings announcement?

Galmed Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Galmed Pharmaceuticals.

Where is Galmed Pharmaceuticals' stock going? Where will Galmed Pharmaceuticals' stock price be in 2017?

3 brokers have issued 1 year price objectives for Galmed Pharmaceuticals' stock. Their predictions range from $14.00 to $19.00. On average, they expect Galmed Pharmaceuticals' stock price to reach $17.00 in the next year. View Analyst Ratings for Galmed Pharmaceuticals.

What are analysts saying about Galmed Pharmaceuticals stock?

Here are some recent quotes from research analysts about Galmed Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for liver diseases and gallstones. Galmed Pharmaceuticals Ltd. is based in Tel Aviv, Israel. " (10/11/2017)
  • 2. Maxim Group analysts commented, "Galmed reported a net loss of $4.8 million, or $0.43 per share, for the three months ending on December 31, 2016 (4Q16). Research and development expenses were $4.1 million. The increase primarily resulted from research and development (clinical trial expenses) associated with the completion of enrollment in the ARREST Study. General and administrative expenses were $0.8 million. Cash and cash equivalents and marketable securities totaled $15.5 million at quarters end. Galmed highlighted the use of the ATM facility raising ~ $4.5 million." (3/24/2017)

Who are some of Galmed Pharmaceuticals' key competitors?

Who are Galmed Pharmaceuticals' key executives?

Galmed Pharmaceuticals' management team includes the folowing people:

  • Chaim Hurvitz, Chairman of the Board
  • Allen Baharaff, Chief Executive Officer, Director
  • Antony Appleyard, Vice President – Drug Development
  • Maureen Graham, Vice President - Regulatory
  • George Tonelli, Vice President - Clinical Operations
  • Tal Yaron-Eldar, External Director Nominee
  • William S. Marth, Independent Director
  • Shmuel Nir, Independent Director

How do I buy Galmed Pharmaceuticals stock?

Shares of Galmed Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Galmed Pharmaceuticals' stock price today?

One share of Galmed Pharmaceuticals stock can currently be purchased for approximately $8.12.

MarketBeat Community Rating for Galmed Pharmaceuticals (NASDAQ GLMD)
Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  174 (Vote Outperform)
Underperform Votes:  65 (Vote Underperform)
Total Votes:  239
MarketBeat's community ratings are surveys of what our community members think about Galmed Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Galmed Pharmaceuticals (NASDAQ:GLMD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $17.00 (109.36% upside)
Consensus Price Target History for Galmed Pharmaceuticals (NASDAQ:GLMD)
Price Target History for Galmed Pharmaceuticals (NASDAQ:GLMD)
Analysts' Ratings History for Galmed Pharmaceuticals (NASDAQ:GLMD)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/6/2017Seaport Global SecuritiesReiterated RatingBuy$19.00N/AView Rating Details
10/5/2017Maxim GroupSet Price TargetBuy$14.00N/AView Rating Details
8/8/2017HC WainwrightBoost Price TargetBuy -> Buy$12.00 -> $18.00HighView Rating Details
8/5/2016FBR & CoSet Price TargetBuy$20.00N/AView Rating Details
7/6/2016Roth CapitalReiterated RatingBuy$6.00N/AView Rating Details
(Data available from 10/18/2015 forward)


Earnings History for Galmed Pharmaceuticals (NASDAQ:GLMD)
Earnings by Quarter for Galmed Pharmaceuticals (NASDAQ:GLMD)
Earnings History by Quarter for Galmed Pharmaceuticals (NASDAQ GLMD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($0.23)N/AView Earnings Details
7/31/20176/30/2017($0.33)($0.22)$0.29 million$0.27 millionViewN/AView Earnings Details
5/15/20173/31/2017($0.39)($0.26)$0.29 million$0.27 millionViewN/AView Earnings Details
3/23/201712/31/2016($0.30)($0.40)$0.22 million$0.27 millionViewN/AView Earnings Details
11/7/2016Q3($0.39)($0.34)$0.19 millionViewListenView Earnings Details
8/3/2016Q216($0.35)($0.39)ViewN/AView Earnings Details
5/16/2016Q116($0.33)($0.36)ViewListenView Earnings Details
3/22/2016Q415($0.28)($0.29)ViewListenView Earnings Details
11/9/2015Q315($0.29)($0.23)ViewN/AView Earnings Details
8/13/2015Q215($0.28)($0.21)ViewListenView Earnings Details
5/13/2015Q1($0.26)($0.22)ViewListenView Earnings Details
3/31/2015($0.36)($0.15)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Galmed Pharmaceuticals (NASDAQ:GLMD)
2017 EPS Consensus Estimate: ($1.28)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.43)($0.25)($0.34)
Q2 20173($0.44)($0.24)($0.36)
Q3 20173($0.39)($0.23)($0.30)
Q4 20173($0.40)($0.22)($0.28)
(Data provided by Zacks Investment Research)


Dividend History for Galmed Pharmaceuticals (NASDAQ:GLMD)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Galmed Pharmaceuticals (NASDAQ:GLMD)
No insider trades for this company have been tracked by


Headline Trends for Galmed Pharmaceuticals (NASDAQ:GLMD)
Latest Headlines for Galmed Pharmaceuticals (NASDAQ:GLMD)
DateHeadline logoGalmed Pharmaceuticals Ltd. (GLMD) Coverage Initiated at Seaport Global Securities - October 7 at 3:36 PM logoGalmed Pharmaceuticals Ltd. (GLMD) Given a $14.00 Price Target at Maxim Group - October 5 at 10:10 PM logoGalmed Pharmaceuticals Ltd. (GLMD) Given a $14.00 Price Target at Maxim Group - October 5 at 10:10 PM logoGalmed Pharmaceuticals Announces Publication of Data on Aramchol™ Mechanism of Action in Hepatology Communications. Data Will Also Be Presented at AASLD - October 5 at 8:27 AM logoContrasting Dynavax Technologies Corporation (DVAX) and Galmed Pharmaceuticals (GLMD) - September 28 at 6:16 PM logo-$0.30 EPS Expected for Galmed Pharmaceuticals Ltd. (GLMD) This Quarter - September 11 at 10:38 AM logo3 Reasons Why Galmed Pharmaceuticals (GLMD) is a Great Momentum Stock - September 6 at 1:32 AM logoGalmed Pharmaceuticals Ltd. (GLMD) Expected to Post Quarterly Sales of $290,000.00 - August 25 at 2:06 AM logoGalmed Pharmaceuticals Ltd. (GLMD) Price Target Increased to $18.00 by Analysts at HC Wainwright - August 8 at 8:08 AM logoGalmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Expected to Announce Quarterly Sales of $290,000.00 - August 7 at 8:58 AM logo Analysts Expect Galmed Pharmaceuticals Ltd. (GLMD) to Post -$0.27 Earnings Per Share - August 5 at 12:44 PM logoGalmed Pharmaceuticals Announces Pricing of Offering of Ordinary Shares to Existing Investors and Members of the Board of Directors - August 3 at 9:09 PM logoQ3 2017 Earnings Estimate for Galmed Pharmaceuticals Ltd. Issued By SunTrust Banks (NASDAQ:GLMD) - August 2 at 7:28 AM logoGalmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Issues Earnings Results - August 1 at 12:28 PM logoGalmed Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update - July 31 at 3:17 PM logoGalmed Pharmaceuticals reports 2Q loss - July 31 at 3:17 PM logoGalmed Pharmaceuticals Ltd. (NASDAQ:GLMD) PT Set at $14.00 by Maxim Group - July 31 at 12:20 PM logoGalmed Pharmaceuticals Ltd. (GLMD) Set to Announce Quarterly Earnings on Monday - July 27 at 11:08 AM logoGalmed Pharmaceuticals Second Quarter 2017 Conference Call and Webcast Scheduled for Monday, July 31, 2017 - July 24 at 9:04 AM logo Brokerages Expect Galmed Pharmaceuticals Ltd. (GLMD) to Post -$0.37 Earnings Per Share - July 14 at 11:19 AM logoTherapix Biosciences (TRPX) Announces the Appointment of Josh Blacher as CFO - May 4 at 12:08 PM logoTherapix Biosciences Announces the Appointment of Josh Blacher as Chief Financial Officer - May 3 at 5:14 PM logoEGLT Gets Long Awaited FDA Approval, PTCT Breathes Easy, GLMD On Track - Nasdaq - January 11 at 11:03 PM



Galmed Pharmaceuticals (GLMD) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.